Portal de investigação
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Anker, SD
- Khan, MS
- Butler, J
- Ofstad, AP
- Peil, B
- Pfarr, E
- Doehner, W
- Sattar, N
- Coats, AJS
- Filippatos, G
- Zannad, F
- Pocock, S
- Packer, M
Unidades de investigação
Abstract
Aims Baseline body mass index (BMI) and weight loss promoted by sodium-glucose cotransporter 2 inhibitors may impact outcomes in patients with heart failure with reduced ejection fraction (HFrEF). We assessed in the EMPEROR-Reduced population treated with empagliflozin versus placebo the relationship between baseline BMI, weight loss and effects on the primary (time to first hospitalization for heart failure [HHF] or cardiovascular death) and key secondary outcomes. Methods and results We categorized patients according to their baseline BMI: < 20 kg/m(2) (n = 180); 20 to < 25 kg/m(2) (n = 1038); 25 to < 30 kg/m(2) (n = 1345); 30 to < 35 kg/m(2) (n = 774) and >= 35 kg/m(2) (n = 393). The treatment effect of empagliflozin on the primary outcome was consistent across all BMI categories (hazard ratios in subgroups 0.66-0.88, interaction trend p = 0.32), as was the effect on total (first plus recurrent) HHF (interaction trend p = 0.31). Empagliflozin reduced the rate of estimated glomerular filtration rate decline consistently across the BMI categories (interaction trend p = 0.67). Overall, incidence rates of any or serious adverse events were comparable between the treatment groups across all BMI categories. A total of 313 (17.4%) patients treated with empagliflozin experienced a weight loss of more than 5% at week 52 versus 230 (12.8%) in placebo. When analysed separately within each treatment group, presence of weight loss was similarly associated with an increased risk of all-cause mortality. Conclusion The benefits of empagliflozin versus placebo were consistently present across all BMI categories in HFrEF patients. Weight loss was associated with higher risk of all-cause mortality, regardless of treatment group.
Dados da publicação
- ISSN/ISSNe:
- 1388-9842, 1879-0844
- Tipo:
- Article
- Páginas:
- 117-127
- DOI:
- 10.1002/ejhf.2728
- Link para outro recurso:
- www.scopus.com
European Journal of Heart Failure Wiley-Blackwell
Citações Recebidas na Web of Science: 16
Citações Recebidas na Scopus: 28
Documentos
- Não há documentos
Filiações
Keywords
- Empagliflozin; Heart failure; Body mass index; Weight loss
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Anker SD,Khan MS,Butler J,Ofstad AP,Peil B,Pfarr E,Doehner W,Sattar N,Coats A,Filippatos G,Ferreira JP,Zannad F,Pocock S,Packer M. Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced. Eur. J. Heart Fail. 2023. 25. (1):p. 117-127. IF:18,200. (1).
